1. Japan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Kidswell Bio Corporation

Kidswell Bio Corporation

TTSE:4584
152.00
JPY
-2.00
(-1.30%)
12.06BMarket Cap
Nov 12Next Earn
Kidswell Bio Corporation
TSE:4584
(Tokyo Stock Exchange)

Recent

price

152.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
43.25
9.56
34.84
33.69
111.61
60.94
55.38
52.31
38.98
34.62
50.86
87.71
68.79
125.47
135.05
- -
Revenue per Share
-67.03
-59.55
-60.04
-82.96
-75.73
-68.5
-47.27
-43.84
-264.65
-34.79
-17.86
-20.77
-40.23
-0.52
-8.48
- -
Basic EPS, GAAP
-75.7
-48.19
-84.38
-101.66
-58.58
-98.41
-22.92
-44.05
-48
-44.14
-37.91
-44.9
-12.83
22.97
-22.82
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
43.74
106.68
110.4
28.26
34.94
182.92
136.08
134.26
53.8
54.36
54.17
38.48
21.35
32.15
33.33
- -
Book Value per Share
43.69
106.64
110.37
28.24
34.92
182.91
136.07
134.26
53.8
54.27
54.07
38.4
21.31
32.14
33.32
- -
Tangible Book Value per Share
5
6
9
10
10
18
19
20
28
29
31
32
35
41
49
49
Basic Weighted Avg Shares
207
61
301
322
1,161
1,089
1,060
1,022
1,078
997
1,569
2,776
2,431
5,082
6,590
- -
Sales/Revenue/Turnover
-128.1
-266.41
-84.24
-160.36
-35.78
-108.73
-86.2
-78.85
-107.76
-97.31
-41.49
-19.84
-54.93
0.55
-2.1
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
1
- -
1
2
1
1
1
- -
- -
Depreciation Expense
-321
-377
-519
-792
-788
-1,225
-905
-856
-7,316
-1,001
-551
-657
-1,422
-21
-414
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
129.01
- -
- -
Effective Tax Rate (%)
-154.98
-622.87
-172.33
-246.28
-67.85
-112.41
-85.36
-83.81
-678.87
-100.49
-35.1
-23.68
-58.49
-0.42
-6.28
- -
Profit Margin (%)
344
894
1,832
1,000
241
3,233
2,287
2,422
2,441
2,232
2,184
2,641
2,549
2,382
3,691
- -
Working Capital
- -
- -
775
775
- -
- -
- -
- -
1,200
1,100
625
1,575
1,838
1,181
2,188
- -
LT Debt
341
888
1,053
271
403
3,500
2,604
2,731
1,487
1,610
1,703
1,234
831
1,411
1,654
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.24
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1.01
- -
- -
Return on Capital (%)
- -
-61.34
-53.51
-119.71
-233.75
-62.74
-29.64
-32.1
-346.86
-64.66
-33.25
-44.78
-137.73
-1.89
-27.02
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
657
363
- -
LT Borrowings
477
2,188
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
50
50
50
Market Capitalization
13,234
12,058
7,048

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
5,469
5,840
- -
Cash, Cash Equivalents & STI
1,542
3,295
- -
Accounts Receivable, Net
1,660
731
- -
Inventories
1,320
364
- -
Total Current Liabilities
3,039
2,150
- -
Payables & Accruals
- -
- -
- -
ST Debt
657
363
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
74.25%
6.5%
17.22%
Free Cash Flow
-31.95%
-115.86%
-219.72%
Net Income, GAAP
254.26%
370.1%
1,858.34%
Sales/Revenue/Turnover
24.61%
52.13%
29.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
5,082
2026
- -
- -
- -
- -
6,590
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
-0.52
2026
- -
- -
- -
- -
-8.48
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Kidswell Bio Corporation specializes in the development, manufacturing, and commercialization of biosimilars and regenerative medicine products. Its main products include biosimilar pharmaceuticals with four biosimilar products already launched by partner pharmaceutical companies in Japan. The company focuses on regenerative medicine utilizing stem cells from human exfoliated deciduous teeth (SHED) and cardiac stem cells (CSC) targeting pediatric diseases, orphan diseases, and intractable diseases. Its new biopharmaceutical segment works on anti-RAMP2 antibodies for cancer and eye diseases and other novel antibodies. The company also advances regenerative medicine therapies using intracardiac stem cells for pediatric congenital heart diseases and dental pulp stem cells for cleft lip, palate, and intestinal ganglion cell deficiency diseases. Recent major changes include the spin-off of its cell therapy business into a wholly owned subsidiary, S-Quatre Corporation, in April 2024 to advance SHED-based therapies and facilitate fundraising and partnerships. The company entered a basic agreement and contract with Alfresa Holdings and others for joint development of biosimilars to establish Japan's first domestic biosimilar supply chain including new development, manufacturing, and stable supply. It also joined a non-binding term sheet with Alfresa Holdings, Mycenax Biotech, and Chiome Bioscience to explore a joint venture focused on GMP manufacturing for biopharmaceuticals in Japan. Kidswell Bio is preparing clinical trial applications for SHED-related treatments and consulting with regulatory authorities to advance its pipeline. It concentrates management resources on biosimilars and cell therapy while promoting collaborations in new biopharmaceutical development. Founded in 2000 and headquartered in Japan, Kidswell Bio operates primarily in the Japanese market with ongoing international collaborations. The company leverages strategic alliances and manufacturing partnerships to enhance its biosimilar portfolio and advance regenerative medicine solutions for complex diseases, maintaining a strong focus on innovation and domestic supply chain stability in biopharmaceuticals. This profile reflects Kidswell Bio Corporation's comprehensive biosimilar product commercialization, regenerative medicine R&D, recent strategic spin-off and partnership ventures, and its role in Japan's biopharmaceutical manufacturing landscape as of late 2025.